Centre Hospitalier De Colmar — Clinical Trial Site

60 Registered trials

33 Currently recruiting

Organisation

Centre Hospitalier De Colmar

Location

Colmar Cedex, France

Identifier

ORG-100028755

Address

39 Avenue De La Liberte, Bp 60535, 68024, France

Departments

1818 :Rhumatologie
1818: Rheumatology
68024
Centre pour Personnes Âgées
Chirurgie pédiatrique
Departement de Neurologie
gastro enterology
GASTRO ENTOROLOGY
gastroentérologie
Gastroenterology
Hematology Department
Hépato gastro-entérologie
Hepato-gastroenterology
Hepatogastroenterology
Infectious Diseases
intensive care
Internal Medecine and Immunology
Internal Medicine
Médecine A - Gastroentérologie
Médecine F
Nephrology
NEUROLOGIE
Neurology/Oncology
Onco-Hématologie Médecine B
Oncologie
Oncologie médicale
Oncologie-Hématologie
oncology
Pneumologie
Pôle de Psychiatrie Générale et Infanto-Juvénile
Pôle Urgence Pasteur
Pulmonology
Radiodiagnostic et Imagerie Médicale
Rheumatology
Service de Cardiologie
Service de maladies infectieuses
Service de Médecine B
Service de Médecine F
Service de Néphrologie
Service de Pneumologie
Urgences

Clinical trials at this site (60)

Search interface

Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended

2024-515944-22-00 BRAFV600E-mutant metastatic Non-small Cell Lung Cancer 4 2021-01-19
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 7 2020-10-30
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Non Small Cell Lung Cancer 5 2019-07-22
Phase III randomised trial evaluating chemotherapy early treatment intensification with temozolomide in adults present with a glioblastoma Ended

2022-500451-23-00 Adults with a de novo glioblastoma 5 2019-03-18
A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignancies Ended

2024-515119-23-00 Phase Ib and Phase II part 1: HPV-16 positive recurrent 9 2017-08-29
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended

2024-518741-21-00 colon cancer 4 2014-12-23
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-02-12
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended

2022-501895-25-00 Polymyalgia Rheumatica 5 2023-09-13
Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended

2022-500363-12-00 SARS CoV-2 (COVID-19) 4 2022-08-24
IFCT-1802 SAVIMMUNE: Immunotherapy in Patient With Poor General Condition Ended

2024-515943-44-00 Non small cell lung cancer 4 2020-10-14
Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo… Ended

2024-514586-20-01 Non small cell lung cancer 5 2018-05-02
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc… Ended

2023-503807-27-00 Biliary tract carcinoma 4